Participants who meet all of the following criteria will be eligible to participate in this study: - Adults aged 18 to 75. - Diagnosis of type 2 diabetes for at least 6 months. - HbA1c between 7.0% and 10.5%. - Body mass index (BMI) between 23 and 50 kg/m². - Body weight stable for the past 3 months before joining. - Stable dose of metformin (≥1000 mg/day), with or without SGLT2i, for ≥3 months. - Women of childbearing potential (WOCBP): highly effective contraception ≥6 months prior to screening, throughout study, and 90 days post-last dose; negative pregnancy test within 24 hrs of first dose; no intent to donate sperm/ova - Agrees to avoid grapefruit/grapefruit products

Participants who meet any of the following criteria will be excluded from this study: - Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or systemic corticosteroids). - Type 1 diabetes or a history of diabetic ketoacidosis. - Use of any GLP-1 receptor agonist within the past 6 months, or any prior exposure to CX11. - Use of insulin to control blood sugar within the past 12 months. - More than one episode of severe low blood sugar, with awareness of hypoglycemia symptoms. - Cardiovascular or cerebrovascular conditions within the past 6 months: - Heart attack, coronary angioplasty, or bypass surgery (diagnostic angiography allowed). - Valvular heart disease or prior heart valve repair surgery. - Unstable angina. - Transient ischemic attack (TIA) or stroke. - Decompensated heart failure (NYHA Class III or IV). - ECG abnormalities indicating significant safety risk, such as supraventricular tachycardia, torsades de pointes, second- or third-degree AV block, myocardial infarction, QTcF > 450 ms in males or > 470 ms in females, PR interval > 220 ms. - Poorly controlled hypertension at screening: systolic ≥ 180 mmHg or diastolic ≥ 100 mmHg. - Pancreatic or gallbladder conditions: - Acute or chronic pancreatitis. - Symptomatic gallbladder disease (previous cholecystectomy is allowed). - Pancreatic injury or risk factors that increase pancreatitis risk. - Thyroid conditions: - Poorly controlled abnormal thyroid function on a stable dose before screening. - Clinically significant abnormal thyroid test results at screening. - Personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) type 2A or 2B. - Cancer history: - Malignancy within the past 5 years, regardless of recurrence or metastasis. Exceptions: localized basal cell skin cancer, low-risk prostate cancer, cervical carcinoma in situ, or high-grade prostatic intraepithelial neoplasia. - Gastrointestinal conditions or treatments that may affect drug absorption: - Abnormal gastric emptying (e.g., gastric outlet obstruction). - Severe chronic gastrointestinal disease, including active ulcer within 6 months. - Crohn's disease, ulcerative colitis, or other inflammatory bowel diseases. - Prior gastrointestinal surgery (except polypectomy and appendectomy). - Long-term use of drugs that directly affect gastrointestinal motility (e.g., mosapride, cisapride). - Liver disease: - Active liver disease other than nonalcoholic fatty liver. - Chronic active hepatitis B or C. - Primary biliary cirrhosis. - Eye disease: - Uncontrolled or potentially unstable diabetic retinopathy or maculopathy. - Abnormal lab results at screening: - eGFR < 60 mL/min/1.73 m² (CKD-EPI). - ALT or AST > 2.5 × upper limit of normal (ULN). - Total bilirubin > 1.5 × ULN (except known Gilbert's syndrome). - Serum amylase or lipase > 1.5 × ULN. - Fasting triglycerides > 5.7 mmol/L. - TSH > 1.5 × ULN or < 1.0 × LLN. - Calcitonin ≥ 20 ng/L. - Hemoglobin < 110 g/L (male) or < 100 g/L (female).